Insulin-Like Growth Factor Binding Protein 3 Chemosensitizes Pancreatic Ductal Adenocarcinoma Through Its Death Receptor

Insulin-Like Growth Factor Binding Protein 3 Chemosensitizes Pancreatic Ductal Adenocarcinoma Through Its Death Receptor Publisher Pubmed

Mofid MR¹ ; Gheysarzadeh A^{2, 3, 4} ; Bakhtiyari S⁴

Show Affiliations

1. Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
2. Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran
3. Department of Biology, Faculty of Science, Ilam University, Ilam, Iran
4. Department of Clinical Biochemistry, Ilam University of Medical Sciences, Ilam, Iran

Source: Pancreatology Published:2020

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies. Gemcitabine and doxorubicin are commonly used as the chemotherapy agents, but most of PDAC tumors eventually acquired resistance to chemotherapy. Accumulating evidence indicates that Insulin-like growth factor binding protein 3 (IGFBP-3) plays a key role against tumor growth but its expression has commonly suppressed. The present study was designed to evaluate IGFBP-3 effects in chemotherapy sensitization of PDAC cells. Here, we report that the re-sensitization of chemoresistant PDAC cells was occurred by IGFBP-3 through recruitment of its death receptor (IGFBP-3R). Using gemcitabine, doxorubicin-resistant PDAC cell lines, we found that IGFBP-3 sensitized chemoresistant cells by activating apoptosis (as evaluated by Bax up-regulation, Bcl-2 down-regulation as well as Caspase-3 and Caspase 8 activation). IGFBP-3R was also found to have higher expression level in resistant AsPc-1 and MIA PaCa-2 cells in comparison to parental cells. IGFBP-3R was also highly expressed in PDAC tumor which exposed to chemotherapy in comparison to un-treated PDAC tumors. In addition, we confirmed our finding by using specific siRNA to knocking down of IGFBP-3R which prevents IGFBP-3 Chemosensitization. Taken together, the present study for the first time indicates the clinical relevance for combining IGFBP-3 with chemotherapy to reduce chemoresistance in PDAC. © 2020

Related Docs

View other Related Docs

1. In Silico Interaction of Insulin-Like Growth Factor Binding Protein 3 With Insulin-Like Growth Factor 1, Research in Pharmaceutical Sciences (2018)

2. Clinicopathological Correlation of Insulin-Like Growth Factor Binding Protein 3 and Their Death Receptor in Patients With Gastric Cancer, Research in Pharmaceutical Sciences (2024)

3. The Insulin-Like Growth Factor Binding Protein-3 and Its Death Receptor in Pancreatic Ductal Adenocarcinoma Poor Prognosis, Journal of Cellular Physiology (2019)

4. The Interaction of Insulin-Like Growth Factor Binding Protein 3 (Igfbp-3) in Insulin-Like Growth Factor (Igf)-Independent System, Journal of Isfahan Medical School (2017)

5. Egfr As a Potential Target for the Treatment of Pancreatic Cancer: Dilemma and Controversies, Current Drug Targets (2014)

6. Immune Checkpoint Inhibition for the Treatment of Cancers: An Update and Critical Review of Ongoing Clinical Trials, Clinical Immunology (2021)

7. Dihydroartemisinin Enhances the Therapeutic Efficacy of Bh3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells Via Inhibition of Mcl-1, Asian Pacific Journal of Cancer Prevention (2024)

8. Identification of B and T Cell Epitope Based Peptide Vaccine From Igf-1 Receptor in Breast Cancer, Journal of Molecular Graphics and Modelling (2017)

Experts (# of related papers)

View all Related Experts

Mohammad Reza Mofid (7)

Mohammad Mardani (1)

Style	Citing Format
MLA	Mofid MR, Gheysarzadeh A, Bakhtiyari S. "Insulin-Like Growth Factor Binding Protein 3 Chemosensitizes Pancreatic Ductal Adenocarcinoma Through Its Death Receptor." Pancreatology, vol. 20, no. 7, 2020, pp. 1442-1450.
APA	Mofid MR, Gheysarzadeh A, Bakhtiyari S (2020). Insulin-Like Growth Factor Binding Protein 3 Chemosensitizes Pancreatic Ductal Adenocarcinoma Through Its Death Receptor. Pancreatology, 20(7), 1442-1450.
Chicago	Mofid MR, Gheysarzadeh A, Bakhtiyari S. "Insulin-Like Growth Factor Binding Protein 3 Chemosensitizes Pancreatic Ductal Adenocarcinoma Through Its Death Receptor." Pancreatology 20, no. 7 (2020): 1442-1450.
Harvard	Mofid MR, Gheysarzadeh A, Bakhtiyari S (2020) 'Insulin-Like Growth Factor Binding Protein 3 Chemosensitizes Pancreatic Ductal Adenocarcinoma Through Its Death Receptor', Pancreatology, 20(7), pp. 1442-1450.
Vancouver	Mofid MR, Gheysarzadeh A, Bakhtiyari S. Insulin-Like Growth Factor Binding Protein 3 Chemosensitizes Pancreatic Ductal Adenocarcinoma Through Its Death Receptor. Pancreatology. 2020;20(7):1442-1450.
BibTex	@article{ author = {Mofid MR and Gheysarzadeh A and Bakhtiyari S}, title = {Insulin-Like Growth Factor Binding Protein 3 Chemosensitizes Pancreatic Ductal Adenocarcinoma Through Its Death Receptor}, journal = {Pancreatology}, volume = {20}, number = {7}, pages = {1442-1450}, year = {2020} }
RIS	TY - JOUR AU - Mofid MR AU - Gheysarzadeh A AU - Bakhtiyari S TI - Insulin-Like Growth Factor Binding Protein 3 Chemosensitizes Pancreatic Ductal Adenocarcinoma Through Its Death Receptor JO - Pancreatology VL - 20 IS - 7 SP - 1442 EP - 1450 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract